je.st
news
U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen
2015-03-19 22:40:00| Biotech - Topix.net
A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once launched, would become the first biosimilar in the United States.
Tags: block
bid
judge
rejects
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||